Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.57 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.44 |
| ▸ | GGT1 | P19440 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7204362 | 0.94 | FOLH1 (0.50) | FOLH1GSRRNPEPSLC6A5CPB2 | |
| SCHEMBL9755508 | 0.85 | FOLH1 (0.50) | FOLH1GSRRNPEPSLC6A5CPB2 | |
| SCHEMBL610134 | 0.82 | GGT1 (0.62) | FOLH1GSRRNPEPSLC6A5CPB2 | |
| SCHEMBL148480 | 0.82 | FOLH1 (0.54) | FOLH1GSRRNPEPSLC6A5CPB2 | |
| SCHEMBL7225798 | 0.82 | FOLH1 (0.54) | FOLH1GSRRNPEPSLC6A5CPB2 | |
| SCHEMBL610133 | 0.82 | GGT1 (0.62) | FOLH1GSRRNPEPSLC6A5CPB2 | |
| SCHEMBL6316197 | 0.82 | FOLH1 (0.54) | FOLH1GSRRNPEPSLC6A5CPB2 | |
| SCHEMBL7198299 | 0.82 | FOLH1 (0.54) | FOLH1GSRRNPEPSLC6A5CPB2 | |
| SCHEMBL7076576 | 0.82 | FOLH1 (0.54) | FOLH1GSRRNPEPSLC6A5CPB2 | |
| SCHEMBL6859366 | 0.82 | FOLH1 (0.54) | FOLH1GSRRNPEPSLC6A5CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602910-B2 | Treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine | ILEX ONCOLOGY, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | ILEX ONCOLOGY, INC. (US) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | DHODH, DDT, HADHB | FOLH1 39/4885GSR 1038/4885RNPEP 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.